Brazil is progressing as a global protagonist in clinical research.

Brazil is experiencing a particularly relevant moment in clinical research. With recent regulatory changes, greater predictability for sponsors, and a more favorable environment for study planning, the country is beginning to have more concrete conditions to expand its presence on the international stage. More than a recurring promise, the possibility of a leading role is beginning to take on more objective contours, supported by advances that directly impact legal security, the operation of studies, and the country's attractiveness for new investments.

Law 14874 – A Milestone in Clinical Research in Brazil

Among the central points of this transformation is Law 14.874 , which brought more clarity to one of the sector's historically most sensitive issues: the supply of medication after the conclusion of clinical studies. Previously, the absence of more defined criteria generated legal and operational uncertainty, especially for international companies interested in conducting research in Brazil. With the new legislation, the scenario now has more structured parameters, favoring safer decisions and more consistent planning.

One of the most relevant aspects of this new framework is the definition of a five-year limit after the product's commercialization for post-study supply. This measure helps replace a logic previously perceived as undefined with a more predictable and balanced model. The rule also covers cases of rare and ultra-rare diseases , standardizing the norm and increasing predictability for all involved.

The legislation also reinforces that post-study provision should not be treated as an automatic and care-based obligation. Its continuity depends on a structured plan , individualized clinical evaluation, and objective criteria for eventual interruption, including situations of technical infeasibility. In practice, this offers a more rational regulatory basis for conducting studies in different therapeutic contexts, without compromising the safety and protection of the patient involved in the study.

Brazil's increased competitiveness in multinational studies.

Another important aspect of this evolution lies in the importation of investigational drugs , especially after the implementation of RDC 945. This regulation brought significant progress in making the process more agile and compatible with the dynamics of global research. One of the main benefits is the possibility of proceeding with the importation of medication even before the study is approved by Anvisa (Brazilian Health Regulatory Agency), which allows for the anticipation of operational steps and expands the preparedness capacity of the centers involved.

This new workflow helps reduce delays and create more favorable conditions for conducting competitive studies. There is also a significant strategic gain in the possibility of initially importing only a portion of the batch, instead of concentrating all the logistical and financial investment at the beginning of the operation. This risk-sharing logic tends to make the process more efficient, benefiting both the sponsor and the operational team of the study.

Alongside regulatory advancements, the current environment offers a more structured foundation for increasingly predictable and integrated operations. The country is  strengthening its capacity to transform more modern regulations into practical efficiency. In this context, the collaboration between international sponsors, regulatory teams, and logistics operators takes on an even more strategic role. This evolution is crucial for reinforcing Brazil's image as a reliable, prepared, and competitive environment for hosting global studies.

New Perspectives for Phase 1 and Phase 2 Studies

The outlook is also positive for attracting phase 1 and phase 2 studies , considered strategic steps for the development of clinical innovation. The combination of greater regulatory certainty, well-established and swift regulatory deadlines, and the strengthening of local capacity creates favorable conditions for a more significant participation of the country in these phases of greater scientific and technical density. This movement expands not only the potential volume of research, but also the quality of the position that Brazil can achieve in the international ecosystem.

Beyond being recognized for its broad patient base and the expertise of its research centers, the country is advancing in building a more mature environment for projects of high scientific and strategic value. This is a central point for a more qualified insertion into the global scenario, especially in a context where sponsors seek markets capable of combining agility, predictability, and excellence in execution.

The moment, therefore, is one of consolidation and opportunity. With a more robust regulatory framework and legal security, established operational experience with prepared research centers, and attractiveness due to the volume of patients, recognized operational quality, and favorable costs, Brazil possesses increasingly solid attributes to expand its presence in international clinical research. As legislation and implementation advance in a coordinated manner, the country positions itself more clearly as a promising hub for global studies and as an increasingly relevant participant in the health innovation agenda.